# Addus HomeCare Corporation (ADUS)

> Source: Nexqual · https://nexqual.com/ADUS · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Addus HomeCare Corporation (ADUS), nexqual.com/ADUS" · informational, not investment advice.

**Price:** USD 122.67 (+4.00% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 117.95 · day 118.38–123.19 · 52w 87.95–124.44 · market cap $2.29B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.48B, net income $105M (7.1% margin), free cash flow $155M (SEC filings).
- Valuation: P/E 21.8x (avg 24.8x at the last 3 fiscal year-ends), EV/EBITDA 13.7x, net cash $38.0M.
- Insider open-market sales, last ~7 months: 4 Form 4 filings, $90K; 2 not under a Rule 10b5-1 plan ($47K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +1.6% vs S&P 500 +14.9%; 5Y +49.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 1.79, revenue estimate $389M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $864M | $951M | $1.06B | $1.15B | $1.42B | $1.48B |
| Gross profit | $270M | $300M | $340M | $375M | $462M | — |
| Operating income | $65.9M | $68.7M | $91.0M | $103M | $139M | $148M |
| Net income | $45.1M | $46.0M | $62.5M | $73.6M | $95.9M | $105M |
| EPS (diluted) | $2.81 | $2.84 | $3.83 | $4.23 | $5.22 | — |
| Free cash flow | $34.8M | $96.8M | $103M | $110M | $104M | $155M |
| Gross margin | 31.2% | 31.5% | 32.1% | 32.5% | 32.5% | — |
| Operating margin | 7.6% | 7.2% | 8.6% | 8.9% | 9.7% | 10.0% |
| Net margin | 5.2% | 4.8% | 5.9% | 6.4% | 6.7% | 7.1% |
| Revenue growth | +13.0% | +10.0% | +11.3% | +9.1% | +23.2% | — |
| Cash + short-term investments | $169M | $80.0M | $64.8M | $98.9M | $81.6M | — |
| Total debt | $221M | $132M | $124M | $218M | $121M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 21.8x · P/S 1.6x · EV/EBITDA 13.7x · EV/Sales 1.5x · P/FCF 14.8x · P/B 2.0x · FCF yield 6.76% · Earnings yield 4.60% · Net cash $38.0M · EV $2.25B
P/E at fiscal year-ends: Dec 2025 20.6x, Dec 2024 29.6x, Dec 2023 24.2x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
2 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Dixon Heather Brianne | President and Chief Operating | 288 | $27K | 0.6% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-05-21 | Lopez Esteban | Director | 250 | $23K | 7.2% | No | Too little history (no open-market trades in 2023) |
| 2026-05-19 | Lopez Esteban | Director | 250 | $23K | 6.8% | No | Too little history (no open-market trades in 2023) |
| 2026-04-21 | Blessing Cliff Donald | EVP, Chief Development Officer | 178 | $17K | 1.4% | Yes | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-14 | B of A Securities | Downgrade | Buy → Neutral | $140 → $125 |
| 2026-08-05 | RBC Capital | Target raised | Outperform | $130 → $134 |
| 2026-07-09 | Barclays | Target raised | Underweight | $92 → $96 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +1.6% | +49.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +1.6% | +8.4% |
| Volatility (annualized) | 29.3% | 32.6% |
| Max drawdown | -27.9% (Oct 2025→Jun 2026) | -32.9% (Jan 2025→Mar 2025) |

## Peers (Medical Care Facilities)
MD (Pediatrix Medical Group, Inc.) USD 29.55 +5.16% · BKD (Brookdale Senior Living Inc.) USD 10.19 +1.09% · GRDN (Guardian Pharmacy Services, Inc) USD 39.59 +1.56% · SGRY (Surgery Partners, Inc.) USD 15.9 +3.25% · ASTH (Astrana Health Inc.) USD 38.01 +1.77% · AVAH (Aveanna Healthcare Holdings Inc) USD 13.32 +2.54%

## More
Full page: https://nexqual.com/ADUS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ADUS's own 10-K filed 2026-02-24 (https://www.sec.gov/Archives/edgar/data/1468328/000143774926005352/adus20251231_10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Oracle (ORCL) | "For financial management, we utilize Oracle's Planning Budgeting Cloud Service as our solution for budgeting, forecasting, and financial reporting and Oracle Fusion for the general ledger, accounts payable and fixed asse…" |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Personal Care | $296.0M | 78.4% | +10.0% | $60.4M | 20.4% |
| Hospice | $64.2M | 17.0% | +3.3% | $12.1M | 18.8% |
| Home Health | $17.2M | 4.6% | -4.8% | $3.3M | 19.1% |
| Total revenue | $377.4M | 100% | — | $75.8M | 20.1% |

## Company outlook (8-K filed 2026-08-03)

- "By delivering a full continuum of care as we scale, we anticipate acting on meaningful synergies and uncovering further growth opportunities throughout the remainder of 2026."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.79 | $1.76 | +1.7% | $388.7M | 13 |
| Next quarter (ends 2026-12-31) | $1.89 | $1.92 | -1.2% | $393.8M | 13 |
| Current fiscal year (ends 2026-12-31) | $7.05 | $7.00 | +0.7% | $1.52B | 14 |
| Next fiscal year (ends 2027-12-31) | $7.52 | $7.48 | +0.4% | $1.60B | 13 |